Publicaciones en las que colabora con María Jesús Monte Río (43)

2024

  1. Impact of liver diseases and pharmacological interactions on the transportome involved in hepatic drug disposition

    Biochemical Pharmacology

  2. Relationship between cholestasis and altered progesterone metabolism in the placenta-maternal liver tandem

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 2

2022

  1. Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers

    Cancers, Vol. 14, Núm. 14

2020

  1. Cellular mechanisms accounting for the refractoriness of colorectal carcinoma to pharmacological treatment

    Cancers, Vol. 12, Núm. 9, pp. 1-34

  2. Clinical relevance of the relationship between changes in gut microbiota and bile acid metabolism in patients with intrahepatic cholangiocarcinoma

    HEPATOBILIARY SURGERY AND NUTRITION

  3. Molecular bases of drug resistance in hepatocellular carcinoma

    Cancers, Vol. 12, Núm. 6, pp. 1-26

  4. Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: A machine-learning approach

    Cancers, Vol. 12, Núm. 6, pp. 1-30

  5. Role of genetic variations in the hepatic handling of drugs

    International Journal of Molecular Sciences, Vol. 21, Núm. 8

2019

  1. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib

    British Journal of Pharmacology, Vol. 176, Núm. 6, pp. 787-800

2018

  1. Interaction of glucocorticoids with FXR/FGF19/FGF21-mediated ileum-liver crosstalk

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 9, pp. 2927-2937

2016

  1. Protective role of biliverdin against bile acid-induced oxidative stress in liver cells

    Free Radical Biology and Medicine, Vol. 97, pp. 466-477

2015

  1. Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT)

    Journal of Controlled Release, Vol. 216, pp. 93-102

  2. Pathophysiological and pharmacological implications of elucidating the molecular bases of the interaction between HBV and the bile acid transporter NTCP

    Annals of Hepatology, Vol. 14, Núm. 1, pp. 143-144

  3. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease

    Journal of Hepatology, Vol. 63, Núm. 4, pp. 952-961

2014

  1. The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy

    Acta Pharmacologica Sinica, Vol. 35, Núm. 1, pp. 1-10

2013

  1. FXR-dependent and -independent interaction of glucocorticoids with the regulatory pathways involved in the control of bile acid handling by the liver

    Biochemical Pharmacology, Vol. 85, Núm. 6, pp. 829-838

  2. Genetic Variants Involved in Intracellular Mechanisms of Chemoresistance to Anticancer Drugs Due to Changes in the Effect on Their Molecular Targets

    eLS

2012

  1. Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta

    Molecular Pharmacology, Vol. 81, Núm. 2, pp. 273-283

2011

  1. A homozygous nonsense mutation (c.214C→A) in the biliverdin reductase alpha gene (BLVRA) results in accumulation of biliverdin during episodes of cholestasis

    Journal of Medical Genetics, Vol. 48, Núm. 4, pp. 219-225

2009

  1. Hepatobiliary transporters in the pharmacology and toxicology of anticancer drugs

    Frontiers in Bioscience, Vol. 14, Núm. 11, pp. 4257-4280